Acumen Pharmaceuticals (ABOS) Interest & Investment Income (2021 - 2026)

Acumen Pharmaceuticals has reported Interest & Investment Income for 5 years, with the latest figure at $1.1 million in Q1 2026.

• Quarterly Interest & Investment Income fell 56.94% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.0 million (down 52.75% YoY) and the FY2025 annual result came in at $7.4 million, down 47.98% from the prior year.
• Interest & Investment Income declined to $1.1 million in Q1 2026 per ABOS's latest filing, from $1.3 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at $4.0 million in Q1 2024 and troughed at $1.1 million in Q1 2026.
• A 4-year average of $2.6 million and a median of $2.7 million in 2024 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2024 and 2026: Interest & Investment Income soared 102.55% in 2024, then sank 56.94% in 2026.
• Over 4 years, Interest & Investment Income stood at $4.0 million in 2023, then dropped by 24.27% to $3.0 million in 2024, then slumped by 55.82% to $1.3 million in 2025, then declined by 19.52% to $1.1 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $1.1 million, $1.3 million, and $1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.